Saturday 17 October 2026
Export ALLO’s income statement to Excel — free account
Allogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023. In the quarter to June 2026, revenue grew 20,990.9%, EPS grew 43.5% and free cash flow grew 17.7%, each against the same quarter a year earlier.
1.31
0.03
−2.24%
Follow ALLO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+8 more quarters Free account |
P/S ratio |
145.41 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(21.38) | — | — | — | |
P/B ratio |
1.57 | — | — | — | |
Price to Tangible BV |
1.57 | — | — | — | |
EV/Sales |
74.72 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(3.44) | — | — | — | |
EV/FCF |
(3.43) | — | — | — | |
Quick Ratio |
10.48 | 9.42 | 7.70 | 7.92 | |
Current Ratio |
10.72 | 9.65 | 7.93 | 8.19 | |
Net Debt/EBITDA |
7.30 | 6.05 | 6.23 | 5.90 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.75 | 0.30 | 0.71 | 0.72 | |
Capex/Depreciation |
(0.11) | 0.00 | 0.00 | (0.11) | |
Interest Coverage |
(136.79) | (153.64) | (135.48) | (130.53) | |
Research and Development Expense of Revenue |
662.09% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
449.12% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
268.10% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.33 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(32.21%) | — | — | — | |
Free Cash Flow Yield |
(15.00%) | — | — | — | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.10) | (0.05) | (0.13) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.05) | (0.13) | (0.13) | |
Cash per Share |
1.01 | 1.11 | 1.13 | 1.14 | |
Shareholders Equity per Share |
1.33 | 1.16 | 1.33 | 1.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.33 | 1.16 | 1.33 | 1.42 | |
Free Cash Flow |
(32.15) | (12.92) | (27.60) | (29.93) | |
Working Capital |
308.27 | 244.96 | 225.24 | 228.89 | |
Capital Expenditures |
(0.15) | (0.01) | 0.00 | (0.24) | |
Net Current Asset Value |
226.08 | 156.21 | 134.39 | 136.28 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.03 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
5.41 | 5.00 | 4.83 | 4.60 | |
Average Assets |
510.34 | 451.97 | 482.31 | 514.45 | |
Average Common Equity |
390.37 | 332.13 | 357.36 | 389.54 |
Columns are period end dates